Fate Therapeutics (FATE) Treasury Shares (2012 - 2026)

Fate Therapeutics' Treasury Shares history runs 15 years deep, the most recent figure standing at $9.3 million for Q1 2026.

• Quarterly Treasury Shares rose 28.42% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 28.42% YoY) and the FY2025 annual result came in at $6.6 million, up 6.79% from the prior year.
• Treasury Shares was $9.3 million for Q1 2026 at Fate Therapeutics, up from $6.6 million in the prior quarter.
• Across five years, Treasury Shares topped out at $9.3 million in Q1 2026 and bottomed at $3.1 million in Q4 2023.
• A 5-year average of $5.5 million and a median of $5.9 million in 2022 frame the typical range for Treasury Shares.
• Annual changes were most pronounced in 2022 — Treasury Shares surged 284.99% — and 2023, when it tumbled 47.72%.
• Fate Therapeutics' Treasury Shares stood at $5.9 million in 2022, then tumbled by 47.72% to $3.1 million in 2023, then jumped by 102.74% to $6.2 million in 2024, then rose by 6.79% to $6.6 million in 2025, then jumped by 40.02% to $9.3 million in 2026.
• Business Quant data shows FATE's Treasury Shares at $9.3 million in Q1 2026, $6.6 million in Q4 2025, and $6.6 million in Q3 2025.